These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31127314)

  • 1. Soluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes.
    Wadén JM; Dahlström EH; Elonen N; Thorn LM; Wadén J; Sandholm N; Forsblom C; Groop PH;
    Diabetologia; 2019 Jul; 62(7):1268-1274. PubMed ID: 31127314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of the receptor for advanced glycation end products (RAGE) -374 T/A gene polymorphism and circulating soluble RAGE with nephropathy in type 1 diabetic patients.
    Abdel-Azeez HA; El-Okely AM
    Egypt J Immunol; 2009; 16(1):95-106. PubMed ID: 20726326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes.
    Thomas MC; Söderlund J; Lehto M; Mäkinen VP; Moran JL; Cooper ME; Forsblom C; Groop PH;
    Diabetologia; 2011 Oct; 54(10):2669-77. PubMed ID: 21607631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes.
    Saraheimo M; Forsblom C; Thorn L; Wadén J; Rosengård-Bärlund M; Heikkilä O; Hietala K; Gordin D; Frystyk J; Flyvbjerg A; Groop PH;
    Diabetes Care; 2008 Jun; 31(6):1165-9. PubMed ID: 18346990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes.
    Thomas MC; Woodward M; Neal B; Li Q; Pickering R; Marre M; Williams B; Perkovic V; Cooper ME; Zoungas S; Chalmers J; Hillis GS;
    Diabetes Care; 2015 Oct; 38(10):1891-7. PubMed ID: 26253728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
    Tan KC; Shiu SW; Chow WS; Leng L; Bucala R; Betteridge DJ
    Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variants in the receptor for advanced glycation end products (RAGE) gene were associated with circulating soluble RAGE level but not with renal function among Asians with type 2 diabetes: a genome-wide association study.
    Lim SC; Dorajoo R; Zhang X; Wang L; Ang SF; Tan CSH; Yeoh LY; Ng XW; Li N; Su C; Liu S; Wong MDS; Low KMS; Yao AO; Babitha J; Fun S; Zhou S; Lee SBM; Tang WE; Tavintharan S; Sum CF; Liu JJ
    Nephrol Dial Transplant; 2017 Oct; 32(10):1697-1704. PubMed ID: 27448675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between the G82S Polymorphism of the Receptor Gene for Advanced Glycation End-products and Soluble Serum Levels RAGE with Diabetic Nephropathy in the White (Asian) Race.
    Rezaei Arnesa A; Hajian S; Salemi Bazargani S; Salahshourifar I; Moghbelinejad S; Abdolvahabi Z; Yaghoobzadeh H; Fathi M; Piri H
    Iran J Kidney Dis; 2024 May; 18(3):179-186. PubMed ID: 38904338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decline in estimated glomerular filtration rate is associated with risk of end-stage renal disease in type 2 diabetes with macroalbuminuria: an observational study from JDNCS.
    Shimizu M; Furuichi K; Toyama T; Funamoto T; Kitajima S; Hara A; Ogawa D; Koya D; Ikeda K; Koshino Y; Kurokawa Y; Abe H; Mori K; Nakayama M; Konishi Y; Samejima KI; Matsui M; Yamauchi H; Gohda T; Fukami K; Nagata D; Yamazaki H; Yuzawa Y; Suzuki Y; Fujimoto S; Maruyama S; Kato S; Naito T; Yoshimura K; Yokoyama H; Wada T;
    Clin Exp Nephrol; 2018 Apr; 22(2):377-387. PubMed ID: 28889347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy.
    Skupien J; Smiles AM; Valo E; Ahluwalia TS; Gyorgy B; Sandholm N; Croall S; Lajer M; McDonnell K; Forsblom C; Harjutsalo V; Marre M; Galecki AT; Tregouet DA; Wu CY; Mychaleckyj JC; Nickerson H; Pragnell M; Rich SS; Pezzolesi MG; Hadjadj S; Rossing P; Groop PH; Krolewski AS
    Diabetes Care; 2019 Jan; 42(1):93-101. PubMed ID: 30455333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smoking and progression of diabetic nephropathy in patients with type 1 diabetes.
    Feodoroff M; Harjutsalo V; Forsblom C; Thorn L; Wadén J; Tolonen N; Lithovius R; Groop PH
    Acta Diabetol; 2016 Aug; 53(4):525-33. PubMed ID: 26668013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
    Nin JW; Jorsal A; Ferreira I; Schalkwijk CG; Prins MH; Parving HH; Tarnow L; Rossing P; Stehouwer CD
    Diabetes; 2010 Aug; 59(8):2027-32. PubMed ID: 20522598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of albuminuria and its association with incident cardiovascular outcomes and mortality in type 1 diabetes: the FinnDiane Study.
    Jansson FJ; Forsblom C; Harjutsalo V; Thorn LM; Wadén J; Elonen N; Ahola AJ; Saraheimo M; Groop PH;
    Diabetologia; 2018 May; 61(5):1203-1211. PubMed ID: 29423580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma sRAGE is not associated with urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage.
    Yu JY; An XF; Liu JS; Ten SC; Wang X; Zhao Y; Huang S; Gu WJ; Gao F
    Diabetes Res Clin Pract; 2010 Feb; 87(2):157-60. PubMed ID: 19945761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingomyelin and progression of renal and coronary heart disease in individuals with type 1 diabetes.
    Pongrac Barlovic D; Harjutsalo V; Sandholm N; Forsblom C; Groop PH;
    Diabetologia; 2020 Sep; 63(9):1847-1856. PubMed ID: 32564139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary adiponectin is an independent predictor of progression to end-stage renal disease in patients with type 1 diabetes and diabetic nephropathy.
    Panduru NM; Saraheimo M; Forsblom C; Thorn LM; Gordin D; Wadén J; Tolonen N; Bierhaus A; Humpert PM; Groop PH;
    Diabetes Care; 2015 May; 38(5):883-90. PubMed ID: 25720601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The serum uric acid concentration is not causally linked to diabetic nephropathy in type 1 diabetes.
    Ahola AJ; Sandholm N; Forsblom C; Harjutsalo V; Dahlström E; Groop PH;
    Kidney Int; 2017 May; 91(5):1178-1185. PubMed ID: 28238338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes.
    Hansen TK; Forsblom C; Saraheimo M; Thorn L; Wadén J; Høyem P; Østergaard J; Flyvbjerg A; Groop PH;
    Diabetologia; 2010 Jul; 53(7):1517-24. PubMed ID: 20396997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats.
    Lu L; Peng WH; Wang W; Wang LJ; Chen QJ; Shen WF
    J Zhejiang Univ Sci B; 2011 Aug; 12(8):652-9. PubMed ID: 21796806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene.
    Kanková K; Kalousová M; Hertlová M; Krusová D; Olsovský J; Zima T
    Arch Physiol Biochem; 2008 Apr; 114(2):111-9. PubMed ID: 18615900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.